SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Today, Alector, Inc. (NASDAQ:ALEC), a $143 million market cap biotechnology firm specializing in biological products, disclosed a strategic plan to reduce its workforce by approximately 13%.

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Shares of NASDAQ ALEC opened at $1.64 on Thursday. The company has a market capitalization of $162.50 million, a P/E ratio of -0.96 and a beta of 0.61. Alector has a 52-week low of $1.55 and a 52 ...

Alector has a 52-week low of $1.38 and a 52-week high of $7.45. The firm has a market capitalization of $139.71 million, a price-to-earnings ratio of -0.83 and a beta of 0.61.

Alector said it has decided to cut about 25 employees, or 13% of its headcount, to reduce costs. The biotech company, which had been developing an Alzheimer drug candidate that missed trial ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Alector Inc. (ALEC) on Wednesday reported a loss of $2.1 million in its fourth quarter. The South San Francisco ...

A webcast of each conference presentation will be available on the "Events & Presentations” page within the Investors section of the Alector website at http ...